Based on a world-class R&D engine, Lycera has built a robust proprietary pipeline of selective immune modulators for the treatment of autoimmune diseases and cancer. In August of 2016, Lycera announced the initiation of a Phase 2 randomized, placebo controlled clinical trial for LYC-30937-EC, in patients with ulcerative colitis (UC). In November of 2016, Lycera announced the start of a Phase 2 randomized, double-blind, placebo-controlled parallel group study designed to assess the efficacy and safety of LYC-30937-EC given orally once daily in subjects with moderate psoriasis. The Company also has a leading position in the development of agonists of RORγ, a master transcription factor, or “master control switch,” with diverse applications in immuno-oncology. In January 2017, Lycera announced the initiation of a Phase 1/2A study designed to find the biologically active or maximum tolerated dose of LYC-55716. Once the recommended Phase 2 dose is determined, the study will be expanded to determine single agent safety and activity in patients with advanced solid tumors.